Novel Coronavirus Vaccine (CHO cell) Phase III clinical trial
Outcome
To evaluate the efficacy and safety of the Recombinant Novel Coronavirus Vaccine (CHO Cell) against s any severity of COVID-19 in a population aged 18 years and above
Sponsor
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Date
-
Subjects
2101 subjects